BAI3, CDX2 and VIL1: A panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas

Histopathology

Volumn 64, Issue 4, 2014, Pages 547-556

  Bari, Muhammad F ^a,b,c   Brown, Helen ^d   Nicholson, Andrew G ^e   Kerr, Keith M ^f   Gosney, John R ^g   Wallace, William A ^h   Soomro, Irshad ⁱ   Muller, Salli ^j   Peat, Danielle ^k   Moore, Jonathan D ^d   Ward, Lesley A ^d   Freidin, Maxim B ^l   Lim, Eric ^l   Vatish, Manu ^m   Snead, David R J ^b,c  

^a Dow International Medical College   (Pakistan)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^g ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^h ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

ⁱ NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^k NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^l ROYAL BROMPTON HOSPITAL   (United Kingdom)

^m UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

BAI3; Biomarkers; CDX2; Gene expression profiling; Immunohistochemistry; Large cell neuroendocrine lung carcinoma; Small cell lung carcinoma; VIL1

Indexed keywords

BAI3; BIOMARKERS; CDX2; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; LARGE-CELL NEUROENDOCRINE LUNG CARCINOMA; SMALL-CELL LUNG CARCINOMA; VIL1;

CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; LUNG NEOPLASMS; MICROFILAMENT PROTEINS; NERVE TISSUE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84895072259     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12278     Document Type: Article

References (29)

1. Travis WD. The concept of pulmonary neuroendocrine tumours. In Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart, WHO classification of tumours. Lyon, France: IARC Press, 2004; pp. 32-33 & 47-48.
2. William WN Jr, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat. Rev. Clin. Oncol. 2011; 8; 611-619.
3. Le Treut J, Sault MC, Lena H et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann. Oncol. 2013; 24; 1548-1552.
4. Rossi G, Cavazza A, Marchioni A et al. Role of chemotherapy and the receptor tyrosine kinases kit, PDGFRALPHA, PDGFRBETA, and MET in large-cell neuroendocrine carcinoma of the lung. J. Clin. Oncol. 2005; 23; 8774-8785.
5. Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum. Pathol. 1998; 29; 272-279.
6. den Bakker MA, Willemsen S, Grunberg K et al. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. Histopathology 2010; 56; 356-363.
7. Ha SY, Han J, Kim W-S, Suh BS, Roh MS. Interobserver variability in diagnosing high-grade neuroendocrine carcinoma of the lung and comparing it with the morphometric analysis. Korean J. Pathol. 2012; 46; 42-47.
8. Asamura H, Kameya T, Matsuno Y et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J. Clin. Oncol. 2006; 24; 70-76.
9. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003; 123; 115S-128S.
10. Marchevsky AM, Gal AA, Shah S, Koss M. Morphometry confirms the presence of considerable nuclear size overlap between 'small cells' and 'large cells' in high-grade pulmonary neiroendocrine neoplasms. Am. J. Clin. Pathol. 2001; 116; 466-472.
11. Travis WD. Lung tumours with neuroendocrine differentiation. Eur. J. Cancer 2009; 45(Suppl. 1); 251-266.
12. van't Veer LJ, Dai H, Van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415; 530-536.
13. Bartlett JM, Thomas J, Ross DT et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 2010; 12; R47.
14. Clement-Ziza M, Munnich A, Lyonnet S, Jaubert F, Besmond C. Stabilization of RNA during laser capture microdissection by performing experiments under argon atmosphere or using ethanol as a solvent in staining solutions. RNA 2008; 14; 2698-2704.
15. Schroeder A, Mueller O, Stocker S et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 2006; 7; 3.
16. He P, Varticovski L, Bowman ED et al. Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum. Pathol. 2004; 35; 1196-1209.
17. Jones MH, Virtanen C, Honjoh D et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004; 363; 775-781.
18. Forbes SA, Tang G, Bindal N et al. Cosmic (the Catalogue Of Somatic Mutations In Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010; 38; D652-D657.
19. Kan Z, Jaiswal BS, Stinson J et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466; 869-873.
20. Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am. J. Pathol. 2003; 162; 19-27.
21. Arac D, Boucard AA, Bolliger MF et al. A novel evolutionarily conserved domain of cell-adhesion GPCRS mediates autoproteolysis. EMBO J. 2012; 31; 1364-1378.
22. De Lott LB, Morrison C, Suster S, Cohn DE, Frankel WL. Cdx2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch. Pathol. Lab. Med. 2005; 129; 1100-1105.
23. Yatabe Y, Koga T, Mitsudomi T, Takahashi T. Ck20 expression, cdx2 expression, k-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J. Pathol. 2004; 203; 645-652.
24. Yamamichi N, Inada K, Furukawa C et al. CDX2 and the BRM-type SWI/SNF complex cooperatively regulate villin expression in gastrointestinal cells. Exp. Cell Res. 2009; 315; 1779-1789.
25. Nambu Y, Iannettoni MD, Orringer MB, Beer DG. Unique expression patterns and alterations in the intestinal protein villin in primary and metastatic pulmonary adenocarcinomas. Mol. carcinog. 1998; 23; 234-242.
26. Nagashio R, Sato Y, Jiang SX et al. Detection of tumor-specific autoantibodies in sera of patients with lung cancer. Lung Cancer 2008; 62; 364-373.
27. Sun L, Sakurai S, Sano T, Hironaka M, Kawashima O, Nakajima T. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma. Pathol. Int. 2009; 59; 522-529.
28. Toyoshima K, Seta Y, Takeda S, Harada H. Identification of merkel cells by an antibody to villin. J. Histochem. Cytochem. 1998; 46; 1329-1334.
29. Kucherlapati MH, Nguyen AA, Bronson RT, Kucherlapati RS. Inactivation of conditional RB by villin-CRE leads to aggressive tumors outside the gastrointestinal tract. Cancer Res. 2006; 66; 3576-3583.